{"version":"company-facts.v1","source":"https://secwatch.observer","generated_at":"2026-06-03T19:44:39.098922+00:00","company":{"ticker":"TEVA","cik":818686,"company_name":"TEVA PHARMACEUTICAL INDUSTRIES LTD"},"pagination":{"limit":100,"returned":5,"next_cursor":null},"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer","facts":[{"fact_type":"earnings_release","fact_key":"4257cf3545311cbec4f0cd0dccc27aff1ea68506","cik":818686,"ticker":"TEVA","company_name":"TEVA PHARMACEUTICAL INDUSTRIES LTD","filed_at":"2026-04-29T23:59:59+00:00","payload":{"eps_text":"GAAP diluted EPS of $0.31","guidance_signal":"reaffirmed","item_codes_triggered":["2.02"],"net_income_text":null,"period_text":"quarter ended March 31, 2026","report_date":"2026-04-29","result_type":"reported_results","revenue_text":"Revenues of $4.0 billion"},"claim":"TEVA PHARMACEUTICAL INDUSTRIES LTD reported quarter ended March 31, 2026 results: revenue Revenues of $4.0 billion, EPS GAAP diluted EPS of $0.31. Guidance reaffirmed.","evidence_excerpt":"Q1 2026 Highlights: Revenues of $4.0 billion GAAP diluted EPS of $0.31 Non-GAAP diluted EPS of $0.53 Cash flow used in operating activities of $40 million Free cash flow of $188 million","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001171843-26-002796","anchor_url":"https://secwatch.observer/filing/0001171843-26-002796#claim-4257cf3545311cbec4f0cd0dccc27aff1ea68506","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/818686/000117184326002796/0001171843-26-002796-index.htm"},{"fact_type":"executive_change","fact_key":"ec55922d7f","cik":818686,"ticker":"TEVA","company_name":"TEVA PHARMACEUTICAL INDUSTRIES LTD","filed_at":"2024-11-12T23:59:59+00:00","payload":{"action":"elected","action_category":"appointment","departure_tone":"not_applicable","effective_date":"2024-12-01","interim":false,"role":"member of the Board","role_category":"director","successor_name":null,"successor_named":false},"claim":"Chen Lichtenstein was elected as member of the Board at TEVA PHARMACEUTICAL INDUSTRIES LTD.","evidence_excerpt":"the Board elected Mr. Chen Lichtenstein to serve as a member of the Board, effective December 1, 2024","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001193125-24-256014","anchor_url":"https://secwatch.observer/filing/0001193125-24-256014#claim-ec55922d7f","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/818686/000119312524256014/0001193125-24-256014-index.htm"},{"fact_type":"executive_change","fact_key":"c36adf54ef","cik":818686,"ticker":"TEVA","company_name":"TEVA PHARMACEUTICAL INDUSTRIES LTD","filed_at":"2024-05-15T23:59:59+00:00","payload":{"action":"appointed","action_category":"appointment","departure_tone":"not_applicable","effective_date":"2024-06-03","interim":false,"role":"Executive Vice President, Global Operations","role_category":"other_named_officer","successor_name":null,"successor_named":false},"claim":"Matthew Shields was appointed as Executive Vice President, Global Operations at TEVA PHARMACEUTICAL INDUSTRIES LTD.","evidence_excerpt":"Mr. Matthew Shields has been appointed as Executive Vice President, Global Operations of Teva and a member of Teva Executive Management, effective June 3, 2024.","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001193125-24-138936","anchor_url":"https://secwatch.observer/filing/0001193125-24-138936#claim-c36adf54ef","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/818686/000119312524138936/0001193125-24-138936-index.htm"},{"fact_type":"executive_change","fact_key":"822d1a6f77","cik":818686,"ticker":"TEVA","company_name":"TEVA PHARMACEUTICAL INDUSTRIES LTD","filed_at":"2024-05-15T23:59:59+00:00","payload":{"action":"will be leaving","action_category":"departure","departure_tone":"routine","effective_date":"2024-06-03","interim":false,"role":"Executive Vice President, Global Operations","role_category":"other_named_officer","successor_name":"Matthew Shields","successor_named":true},"claim":"Eric Drapé departed as Executive Vice President, Global Operations at TEVA PHARMACEUTICAL INDUSTRIES LTD.","evidence_excerpt":"Mr. Eric Drapé, Executive Vice President, Global Operations, will be leaving Teva Pharmaceutical Industries Ltd.","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001193125-24-138936","anchor_url":"https://secwatch.observer/filing/0001193125-24-138936#claim-822d1a6f77","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/818686/000119312524138936/0001193125-24-138936-index.htm"},{"fact_type":"earnings_release","fact_key":"56f0127c8b9496db532fb0bf5d4d3d0fb941f40e","cik":818686,"ticker":"TEVA","company_name":"TEVA PHARMACEUTICAL INDUSTRIES LTD","filed_at":"2024-05-08T23:59:59+00:00","payload":{"eps_text":"GAAP loss per share of $0.12","guidance_signal":"reaffirmed","item_codes_triggered":["2.02"],"net_income_text":null,"period_text":"the quarter ended March 31, 2024","report_date":"2024-05-08","result_type":"reported_results","revenue_text":"$3,819 million"},"claim":"TEVA PHARMACEUTICAL INDUSTRIES LTD reported the quarter ended March 31, 2024 results: revenue $3,819 million, EPS GAAP loss per share of $0.12. Guidance reaffirmed.","evidence_excerpt":"TEVA REPORTS FIRST QUARTER 2024 FINANCIAL RESULTS AND REAFFIRMS 2024 FINANCIAL OUTLOOK • Generics business and AUSTEDO ® growth lead Q1 2024\nperformance. • Q1 2024 revenues of $3.8 billion reflect an increase of 5% in local currency terms, compared to Q1 2023. • Generics business growth across all regions – increased by 9% in local currency terms globally, compared","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001193125-24-133759","anchor_url":"https://secwatch.observer/filing/0001193125-24-133759#claim-56f0127c8b9496db532fb0bf5d4d3d0fb941f40e","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/818686/000119312524133759/0001193125-24-133759-index.htm"}]}